Your Theranostics Questions Answered – Access, Safety, & What to Expect

In this special Ask Us Anything episode, host Christine VanTimmeren and Dr. Brandon Mancini, Medical Director at BAMF Health, answer questions submitted by listeners about theranostics and radiopharmaceutical therapy.

How accessible are these treatments? Are they covered by insurance? What cancers can be treated today—and what’s coming next? How much radiation are patients and caregivers actually exposed to? And what can patients expect during a treatment visit?

Dr. Mancini provides straightforward answers to some of the most common questions he hears from patients and families, including:

•  The biggest barriers to expanding access to theranostics 
•  Insurance coverage and affordability of FDA-approved treatments 
•  The future of radiopharmaceutical therapy and ongoing clinical trials 
•  Alpha vs. beta therapies explained 
•  Radiation safety for patients, caregivers, children, and pets 
•  What to expect during Pluvicto® and Lutathera® treatment appointments 

Whether you're considering treatment yourself, supporting a loved one, or simply curious about the future of precision medicine, this episode offers practical answers to help you better understand theranostics and the role it's playing in cancer care.

Chapters

00:00 Introduction & Listener Q&A
 00:59 What Limits Access to Theranostics?
 03:48 Why Demand Exceeds Capacity
 04:02 Is Theranostics Covered by Insurance?
 06:11 Accessibility vs. Self-Pay Treatments
 08:16 What's Next for Theranostics?
 09:30 One Drug, Multiple Cancer Types
 10:35 The Future of Combination Therapies
 12:45 Alpha vs. Beta Radiopharmaceuticals Explained
 14:57 Radiation Safety for Patients & Caregivers
 18:55 Why BAMF Compares Radiation to Bananas 🍌
 20:47 Radiation Exposure From Flying vs. Treatment
 21:33 What to Expect During a Pluvicto® Treatment
 24:05 How Lutathera® Treatment Is Different
 25:57 Preparing Patients for Therapy
 26:34 Education, Safety & Setting Expectations
 27:12 Release Criteria & Going Home Safely
 28:32 Closing Thoughts & Future Q&A Episodes

Connect with the hosts on LinkedIn
Dr. Brandon Mancini
Christine VanTimmeren

Connect with BAMF Health
Our Website
Our Podcast

Transcript

Christine VanTimmeren 0:05

Welcome to the BAMF Health Podcast. Today you see it is just Brandon, Dr. Mancini, and I, and that is because we are dedicating this episode to answering your questions. So we put out a request across social media asking for your questions about precision medicine and about theronostics, and you delivered. So thank you to everyone who asked questions. And we want to get right to it. There were a lot of questions about what it's going to take to make precision medicine, theronostics accessible, affordable. This is essentially what BAMF is all about, making accessible affordable as soon as possible. So what are some of the things, the barriers that might be getting in the way of accessibility and affordability? And also what are maybe the misconceptions about the realities of how accessible and affordable it truly is?

Dr. Brandon Mancini 0:58

Sure. I mean, I think big picture when you look at theronostics entering the world of oncologic care, so cancer therapies, it more or less kind of came out of nowhere as far as the volume in a very short period of time. So if we just date back, it was March 2022 when the drug for prostate cancer was approved. And now the volume of patients that could qualify for a theronostic treatment or a targeted radiopharmaceutical medicine went from kind of tens of thousands up to hundreds of thousands, basically overnight. And there's things that kind of remain the same. Those specifically being infrastructure, so the buildings at which therapies are delivered, kind of the workforce, who those people are, where they're located, and then just the whole logistical process of delivery. So I always say infrastructure, workforce, logistics are kind of those rate limiting steps. Since 2022, we've had the approval of the prostate cancer medicine in a whole nother kind of status of the disease for prostate cancer, which has tripled the number of patients that are eligible. But again, the infrastructure, workforce, and logistics have more or less kind of trickled up in kind of their ability to handle such volume. Okay. And why this matters is because radiopharmaceutical medicines are much different. It's not a pill that you can pick up at a pharmacy. It's not uh just a simple uh 30-second infusion. These are radiopharmaceutical medicines that have to be produced at a certain time before the medicine is delivered or it expires because the radioactivity goes away. You have to have special licenses as providers and as uh centers or institutions to be able to deliver these things. You have to have specialty trained nurses and nuclear medicine technologists and physicians and medical assistants and beyond to be able to have experience in doing that in a safe, consistent manner. And then logistics, um, we actually experienced this back in 2022, 2023, where um the launch of that prostate cancer drug took place. And then they found out very quickly that if they just missed a production week, they lost hundreds, if not thousands, of doses. And now logistically, they had to try to make up for all this across the country. So again, the ability to be consistent in that process uh has taken place as well. So at BAMF Health, as you know, I mean, obviously we're created to solve a lot of these problems because the infrastructure across the whole country needs a big time overhaul. And I think what's most evident is if you just look at the numbers. So in 2025, there were about 46,000 treatments for prostate cancer given for this diagnostics uh space. The number of cycles that could have been given was like 400,000. Oh, wow.

Christine VanTimmeren 3:48

So it's like a huge discrepancy there.

Dr. Brandon Mancini 3:50

And so again, it's all those three factors that factor into that. Um, but that's definitely what makes it such a challenge and or such a different uh therapy as it's entered the market uh over the years.

Christine VanTimmeren 4:02

So and when it before it got even to the United States, it was a sort of self-pay thing that people would travel to Germany to receive. Here in the United States, when Pluvicto and specifically was approved, it was also insurance approved. So it is covered by insurance, as is Lutathera, the other drug that we also administer to patients. So this isn't a self-pay situation. This isn't a situation for the wealthy and those with means. It is accessible to all of those who qualify, correct?

Dr. Brandon Mancini 4:39

Yeah, and it was really kind of in a neat way. So when just that March 2022 example, so literally six weeks after Pluvicto, the prostate cancer medicine, was approved for prostate cancer treatment, six weeks later, it was in the national guidelines. And that's a big time step because most healthcare insurance providers follow the national guidelines to be able to advocate for your patient to uh how they build their uh compendia and the way that they cover medications. So the fact that it went from approval to in guidelines in six weeks. Now, as an ordering provider, you can go and submit to insurance consistency consistently and say, look, we're just following the guidelines here and so forth. And so that's kind of the end all be-all for the most part, as far as getting coverage. And so again, that six-week period of time was pretty quick when it's all said and done. Um, and also Medicare is very quick to create these approvals when the FDA approvals come out as well. And that also sets off the cascade. And so, to your point, whether it's Medicaid, Medicare, private insurance, um, these are things that are readily covered in a very uh expeditious manner, um, which is great. And it's something to your point, like when this was not approved in the United States, there were clinical trials with which people could participate in. But like access to that might be difficult. There's only a certain number of centers across the country that do it. Um, and some of the compassionate use programs are can be a little more challenging if patients were trying to seek it. And so that's why they would go overseas.

Christine VanTimmeren 6:11

So there are some health trends and things that are certainly a self-pay insurance won't take care of sort of thing. Those emerging trends and and new options and theranostics , at least for prostate cancer, neuroendocrine tumors, is not that. Like you said, it is accepted, it has been proven, and it is insurance covered. So anyone who qualifies can get access.

Dr. Brandon Mancini 6:40

Right. Yeah. And I think a lot of times in the United States, there's the good and the bad. The good is that access to things that have been fully vetted through rigorous clinical trials and studies can happen pretty quickly. Um, and especially now with some of the changes in the FDA, there's fast track designation, there's quicker approvals, there's a priority uh to get useful novel therapies to people more quickly. So I think a lot of the evolution in that space um has helped or will help over the last five to 10 years in general. Um, and so those things from a regulatory perspective are gonna help people get the therapies that they want. And then it can sometimes put up these barriers, though, right? So, like pluvicto for prostate cancer, if that wasn't approved, that's a tens of thousands of dollar per treatment medication. So that's kind of the bad that I'm referring to is that the price point for someone to be able to electively do a treatment that might be novel if it's not approved is really uh unable to be achieved. And so um, yeah, the the thing is that it's important to continue to go down the pathway of uh proven therapies and push the science. And again, at BAMF Health, right? The number of clinical trials that we do in this space, um one of our major goals is to expedite that whole process for things to move quicker with our existence as opposed to what it would be if we didn't exist. And that's what's been pretty remarkable. So even in our clinical trial space, getting these novel therapies to patients that may not have other options, uh, we have that ability.

Christine VanTimmeren 8:16

So another question people were asking is about what's next for Theranostics. So, like we said, we know it's doing really well for prostate cancer, neuroendocrine tumors. And people might wonder, why is it only those two conditions? What's next? What are the next conditions to have a treatment like this? Um, so what are your thoughts on what could be next in terms of the conditions that can be used or treated?

Dr. Brandon Mancini 8:40

Yeah, I mean, it's a great question. I think there's over a hundred trials going on right now in Theranostics. And because it's a new budding kind of subfield of medicine, a lot of them are those early phase trials, meaning that they got to make sure these things are safe, that they work, and then you kind of continue to escalate that, like we learned from Dan at a prior on a prior episode. Um, but the beauty of it is more of the targets, right? To your point, prostate cancer, it was one target and that treats prostate cancer, essentially. Lutathera, so neuroendocrine tumor treatment, one target treats that tumor. A lot of the novel developments in these clinical trials is they're finding targets that applied to a multitude of tumors simultaneously.

Christine VanTimmeren 9:26

So you get one drug and multiple cancers it can treat.

Dr. Brandon Mancini 9:30

So, for example, we have clinical trials that five or six different types of cancer types are eligible. So colon cancer, breast cancer, lung cancer, uh, pancreatic cancer. Um, so it's more of kind of what they call a basket trial. And that's super important. And it also speaks to where medicine is going. So it's not, you don't just treat lung cancer. What the future is gonna be is you treat lung cancer that has all of these unique biologic changes and markers and proteins and this, that, or the other, which could also be shared with breast cancer or colon cancer. And so the point being that there's gonna be a lot of momentum and you're gonna see approval of radioligand treatments that will actually apply to many cancers all simultaneously. Um, and that's what's super exciting, right? Getting uh more people more options more quickly. Um, I believe right now we have clinical trials that cover about 15 different tumor types. So not only what we do each and every day as those FDA approved treatments, but a whole number of other tumors uh where people need options.

Christine VanTimmeren 10:34

So one thing I've always been curious about is this idea that people's cancer is not homogeneous. It doesn't just have one target on all of its cells, it has multiple. So if a radio pharmaceutical therapy kills some, it might not kill all because it doesn't have that target. So is that part of what could be coming next to is understanding do you use two different types to treat one type of cancer?

Dr. Brandon Mancini 11:01

Yeah, absolutely. I think we've seen that as well because prostate cancer, um, there's trials that have two or three other different targets that they're trying to illuminate and prove out, meaning that prostate cancer has the target that Pluvicto attaches to, but it also has the others. So I think you're hit the nail on the head. I mean, you're gonna see likely combinations of different radiopharmaceuticals. And it might be that you get that PET scan, right? You get the scan that shows you is the target there, and you might get the other PET scan for the other target, and you see if that one's there and maybe that person needs both therapies at the appropriate dosing and intervals and things like that. I think that also uh goes into kind of the future of these treatments as well, because combination therapies is kind of a buzz phrase uh on LinkedIn and throughout kind of all the medical communities where we know that theranostics works. We know that it does a lot of good for extending quality and quantity of life, but everyone wants to make it work better and for more. And some of that involves maybe you do a radiopharmaceutical treatment and you do an immunotherapy. So you use the radiopharmaceutical to kind of destroy the DNA or kind of hurt the actual cancer cells, and you follow that with an immunotherapy, which wakes up your immune system to help treat that cancer as well. Maybe it means giving the radiopharmaceutical with a touch of chemotherapy or a touch of a targeted pill from an oncologist to make sure that the DNA of the cancer cell is as sensitive as it can be, so it's damaged more easily by the radiation. And so there's a lot of novel approaches and ways of looking at it to try to enhance what we're experiencing every day.

Christine VanTimmeren 12:44

Something else that uh someone asked about was this idea of the alpha versus beta treatments, because besides having different targets, you have this idea of alpha versus beta, which I can't even begin to explain. So explain what that is and the differences there.

Dr. Brandon Mancini 13:03

Sure. Yeah, the vast majority of treatments that we do, so both FDA-approved treatments are beta emitting radioisotopes. So what does that mean? That means how I explain it to patients is it's kind of a slow, gentle radiation. And that slow, gentle radiation is still deposited in tissue over a maximum of, say, one to two millimeters, with the majority of it actually being much uh tighter than that. But it's kind of this kind of continuous, kind of slow punch to the DNA. And as a result of that, you actually need thousands of little molecules connected to a tumor spot to simultaneously shoot that radiation in a gentle, controlled way in order to get a positive effect. Now, the alphas are kind of the buzz as well within uh theranostics and radiopharmaceutical therapy. What that is, is a radiopharmaceutical medicine that packs a really strong short punch uh to again the cancer's DNA. So, what that means is you actually need less of those. So you might need tens or hundreds of molecules instead of the thousands. So you might get more out of these alpha therapies, um, depending on kind of what you're treating, as a result of that. So alpha, short, strong punch, beta, soft, gentle punch, both of them effective at kind of killing off cancer cells and damaging the cancer's DNA. Um, but something that's definitely evolving. In alpha therapy, what you have to look out for then is if it's gonna hurt the cancer more, then we need to make sure that it doesn't cause side effects to our body. Okay. Because these treatments are very well tolerated in general. Um, but as we kind of go down the road of novel targets and novel uh treatments and dosing and intervals and alpha versus beta, um, there's gonna be some uh need to understand and just make sure that we're not seeing side effects that wouldn't have emerged if it was beta.

Christine VanTimmeren 14:56

Okay.

Dr. Brandon Mancini 14:56

Yeah, yeah.

Christine VanTimmeren 14:57

Well, on the topic of radiation and radioactivity, we get a lot of questions too about radio pharmaceutical safety, exactly how much radiation are patients getting, or if a loved one is coming to visit a patient when they're getting their treatment, what sort of exposure do they get? So a couple questions here to start with. First, someone who is going to a treatment with a loved one or even just walking into BAMF Health, what is their real exposure level, so to speak?

Dr. Brandon Mancini 15:28

Yeah. So I mean, the principles of radiation safety is ALARA. So as low as reasonably achievable. And obviously, anytime you're dealing with radioactive substances, the goal is to, if the person's getting the radiation treatment, then that's okay. For everyone else, it should be as close to zero as possible. So that's definitely the principle in the way. Um, as far as accompanying a loved one to an imaging or a therapy uh appointment, uh, we do kind of recommend manners with which we create distance. So uh time distance and shielding are kind of the ways of radiation safety. And by creating space between the person that got the radioactive injection versus the person that's accompanying them is a really good, straightforward way uh to keep that person's dose as low as possible. So at BAMF Health for treatment administration, for example, um, it's kind of nice because everybody gets their own treatment room, but we've also set up seating right outside of the treatment room so the loved one or the friend can kind of hang out and they can still talk and they can still converse and have uh somebody accompany them, but that person's now safe because they're a number of feet away where their exposure to the radiation is really low. So your average person during that process is not going to receive any or just very negligible low amounts of radiation. Um, and so in consultations, though, we go through kind of what a whole exposure could look like for the whole cycle of treatment. Um, so pluvicto is given once every six weeks for up to six times, Lutathera for the neuroendocrine tumor is once every eight weeks for up to four times. And really, there's a 72-hour period once someone goes home, with which patients and caregivers or loved ones need to just be cognizant of their activities. Um, I typically explain to patients, they're kind of like a light bulb emanating radiation to about a three-foot radius. And so you want to minimize time within that three-foot radius. And so by far, the two most important things would be um sleeping arrangements. So if someone sleeps next to someone else in the same bed for 72 hours or for three nights, typically sleeping in a separate location is the most advised because that's an easier way to remain three feet away when it's all said and done. Uh, the other thing with radiopharmaceutical treatments is that our urine is radioactive because of the way that it's filtered through the body. And so typically, if possible, using a separate bathroom for those three days or we give teaching uh as far as uh cleanliness or ways of flushing the toilet if someone has only one bathroom. Those two kind of interventions, so sleeping arrangements and bathroom use, that that's kind of your vast majority of any radiation exposure that one could uh experience. But um, if someone, if they're eating dinner together, they we're pretty close to three feet away, right? Yeah. You can be at the same dinner table, you can be in the same living room. Even car rides are okay over short distances. We just typically would have someone be front, back seat, opposite sides, uh, if able. Um, but really the emphasis is just it's incredibly, incredibly safe. And by doing these little metrics to kind of minimize that exposure, the long-term risk to the other person is basically negligible. You can give your hug or kiss goodnight, you can uh do things like that, but it's really just the immediacy, controlling the controllables of the extended exposure.

Christine VanTimmeren 18:55

So we have kind of a unique tool we use to describe exposure to radiation or lack of exposure uh when you're at our facility. So we have a little pamphlet that people can see. If they if you ever get into our Radio pharmacy, you're gonna see a pamphlet like this that compares radiation exposure to bananas. This is wild. I never would have thought that we'd be making a comparison like this. But explain to me, why are we comparing radiation to bananas?

Dr. Brandon Mancini 19:24

No, it's a great question. And a really actually little known fact, and I didn't know this until really getting into the radiation safety aspects. So because bananas contain potassium, some of that potassium comes from, well, it all comes from Earth, but it's radioactive, a very small component. And this radioactivity is completely negligible, right? There's background radiation, et cetera, um, when it's all said and done. But basically, we did a study at our center that the caregiver, the friend, the loved one that accompanies a patient that receives pluvicto or lutothera for every kind of three-day cycle of that three foot for three days exposure, um, they receive the amount of radiation equivalent to eating two bananas in that three-day period. I personally eat a banana every single day. I don't think twice about it, right? And so, again, the point being that again, it's not zero radiation, but when you kind of bring out the practicality of it, it really alleviates a lot of the stress or anxiety kind of that could be accompanied that people come in with at the time of consultation, right? They say, I hear you're radioactive and it's a scary thing to hear. Um, but when you kind of break it down and the practicality is super helpful. Um, so again, bananas are radioactive, very, very low amount. Um, people may not know, but flying on an airplane is actually much more radiation. That's like 400 bananas flying in the air, right?

Christine VanTimmeren 20:47

To 400, that's a big leap.

Dr. Brandon Mancini 20:49

Yeah. And people don't overly think about uh flying in a concerning way from a radiation exposure. So it's really just to provide comfort, ease any stress, and make sure. The other thing that comes up a lot would be kind of pet exposure. Oh, yeah. That would be the number one thing after just the general discussion. Luckily, because of um kind of just the manner with which it happens, um, pets are at incredibly low risk for any harm. Um, any sort of radiation exposure, if someone was exposed to a high dose, um, it would actually take many years on average to cause any outward changes. And so um pets in the same limited 72 hours, it's very negligible as well. So good.

Christine VanTimmeren 21:28

Alright. Don't worry, your pets are fine. When you go home, your pets are fine.

Dr. Brandon Mancini 21:32

Yep.

Christine VanTimmeren 21:33

Uh some other questions we often get are, again, the very practical ones. If I'm coming in for treatment, if I'm seeking treatment for prostate cancer at BAMF Health, what does that process look like? What does it involve? How long am I going to be doing this? So I guess start starting with pluvicto. What does a treatment process look like?

Dr. Brandon Mancini 21:53

Yeah. So we always meet with everyone in consultation, and then they everybody that uh is going to receive pluvicto. So they need one of those PSMA PET scans, right? You need the PET scan to figure out and ensure that the prostate protein is located in the cancer spots or on the cancer spots. So if they haven't had that, we'll order that and we'll get that done as soon as possible. If they've had that already, then after the consultation and education session, we move forward with getting the authorization, et cetera. So normally after that consult, uh people are coming back within just a week or two on average to get their first treatment. Uh when they come in for treatment, they're taken back to their own private room. They have their own bathroom and television. And again, that loved one or friend can hang out with them outside and make sure they're safe. Um, they come in, uh, get them comfy in a chair. We too put two bottles of water in front of front of them and have them start working on those. Um, kind of as I alluded to, the majority of this pluvicto or lutathera that doesn't stick to the tumors will come out through the urine. And so that means we want to drink a lot of fluid to flush the system quite a bit. So we just make sure they start that process. Um, we do have an IV placed then in one of the arms. Um, and then after they've worked on their water for a little bit, uh the nuclear medicine technologists will wheel in their cart. On that cart is a little lead line box. They open that up and they pop out the pluvicto. It's literally looks like water in a syringe. And so um they they kind of quickly and safely hook that up to the IV. That IV push is then 30 to 60 seconds. Um, it's painless. Um, you don't feel anything, you don't see anything, you can't react to it. So there's no like allergy risk because it's literally just radioactive water going in. And so we don't need things like Benadryl or steroids or anything to prevent any sort of reaction. Um again, 30 to 60 seconds. The patient then uh finishes up their water, IV comes out, and they're free to go home. And uh it's again, that whole process is maybe 40 to 60 minutes when it's all said and done for Pluvicto. So um not an overly extensive period of time. And luckily, people feel generally good throughout that process in the hours that follow.

Christine VanTimmeren 24:04

So and then Lutathera is similar, but slightly different. Explain explain the difference there.

Dr. Brandon Mancini 24:10

Yep. So Lutathera, the big difference there is that the infusion, so the actual radioactivity um needs to go in over a slightly slower period of time. So it's instead of like that 30 to 60 second push, it's more of like a 25 to 35 minute infusion. Um, the main reason for that is there's a super, super low risk that the treatment could cause a kind of little hormone reaction in the body that could cause flushing and sweats and heart palpitations. And the odds of this are about 0.5%. Yeah. But as that precaution, everyone just gets that slower type of infusion. Now, accompanying the Lutathera is that someone has an infusion of amino acids, um, lysine and arginine specifically. And amino acids are literally the building blocks of protein, right? They're in everything we eat. But some very smart people long ago figured out that if you give this amino acid for 30 minutes before Lutathera, 30 minutes during Lutathera, and three hours after Lutathera, it sticks to the kidneys and just prevents the any Lutathera of sticking at all as it processes through. And so it just makes sure that the radiation dose to the kidneys is as low as possible. And so it is a much more protracted treatment day. Um, so people are typically hanging out with us for like five hours because of that, really. So the treatment is 25 to 35 minutes, but those amino acids are four hours total. And so it's a lot more of a commitment. Now, luckily, that's once every eight weeks for four times. Um, so it is fewer and it's a wider interval. Um, but that's the main difference. And again, the amino acids are essentially just to kind of stick to the kidney to make sure the Lutathera passes through into the urine and doesn't create any kidney changes long term.

Christine VanTimmeren 25:56

So that's fascinating. Yeah, for anyone who's ever wondered how the heck does this work, this crazy radioactive treatment. I mean, when I talk to patients and I ask them, have you ever heard of this? Did you ever think you'd be getting a radioactive drug? You know, no, no, I never expected anything like this, never heard of anything like this. So there's a lot of questions and there's a lot of, I don't understand how this works. And I think you and our team do a fantastic job of making sure that everyone who comes fully understands that process, is on board with that process, and there are no surprises.

Dr. Brandon Mancini 26:33

Sure.

Christine VanTimmeren 26:33

Yeah.

Dr. Brandon Mancini 26:33

Yeah. And we really emphasize education. Um, so not only at the time of consultation, but then the nurse comes in for the whole radioactive conversation. We give a nice handout, um, an explanation regarding uh around it. So it's all about the preparation. And then we reiterate that at every appointment. And so it's just those nice reminders and involvement and yeah, trying to make people as prepared and as safe as possible.

Christine VanTimmeren 26:59

And no, people are not walking around radioactive, emitting radioactivity into people all around the community. It is extremely minimal. We wouldn't let patients leave our facility if that was the case.

Dr. Brandon Mancini 27:12

So that's a good point, though, because yeah, everybody has to meet what's called release criteria. Um, people might have heard of Geiger counters, right? It's those chirping things that gets close to radioactivity, it chirps really fast. Um, so everybody in America, it's an outpatient procedure, meaning you get the treatment, you go home. And everybody has to and does meet these release criteria. So these are defined criteria where someone cannot be released to the public if they don't meet that threshold. And luckily, with the doses and the type of medicines we deliver, none of it ever exceeds that criteria. So to your point, incredibly safe uh for immediate discharge and to be in public and does not uh cause any increased risk for anybody else.

Christine VanTimmeren 27:52

Yeah, our nuclear medicine technologist will walk up to the patient with a what do you call it? What did you call it? The Geiger counter. Yeah, the Geiger counter. Walk up to them, see what the number is or what it says before the patient is allowed to leave. So there is a physical thing that that measures that.

Dr. Brandon Mancini 28:09

Yeah. Yeah. So many checks and balances. Uh, again, it's all about safety. Um, and it's it's just a neat thing because it it gives it provides that reassurance to the patient, their family member, um, the reassurance to everybody else too, that's involved in their care that everything makes sense and you have certain uh criteria that need to be met to be able to be out and about uh after getting that treatment.

Christine VanTimmeren 28:32

Well, if you have watched this and you say, I have a million other questions, please feel free to send those our way. We would love to hear those questions. If we get enough of them, we can do another episode to answer your questions as well. So reach out to Brandon or I or BAMF Health if you have questions. And thank you for walking through the answers to those. Absolutely. I appreciate it. Yeah, and thank you to those of you who submitted questions. We really appreciate it. All right, that's all for today. We'll see you next time.

Dr. Brandon Mancini 29:00

Take care.